Navigation Links
Omeros Corporation Reports Third Quarter 2013 Financial Results
Date:11/7/2013

nt to the end of the quarter, Omeros received a payment of $12.5 million from CCIC pursuant to the terms of the settlement agreement. Omeros also received $4.9 million in net proceeds from the sale of 373,700 shares of its common stock, sold at an average price of $13.29 per share, pursuant to the company's at-the-market equity facility in October 2013.

About Omeros CorporationOmeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system. Derived from its proprietary PharmacoSurgery® platform, the Company's lead drug product, OMS302 for lens replacement surgery, is currently under review for marketing approval by both the US Food and Drug Administration and the European Medicines Agency with commercial launch planned for the second half of 2014. Omeros' five other clinical programs are focused on schizophrenia, Huntington's disease and cognitive impairment; addictive and compulsive disorders; complement-related diseases; and preventing problems associated with surgical procedures. Omeros also has a proprietary GPCR platform, which is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the "safe harbor" created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-l
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
2. Omeros to Present at the 12th Annual Needham Healthcare Conference
3. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
4. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
5. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
6. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
7. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
8. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
10. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
11. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced four ... million and provides a good start to Q4.  The orders are ... and one in the Middle East . ... said Peter Bruijns , President & CEO. "Total bidding activity ... they have been for any complete year since the company has ...
(Date:10/20/2014)... N.J. (PRWEB) October 20, 2014 ... the Sidney Kimmel Cancer Center at Thomas Jefferson ... , Through the Strategic Alliance Partnership program, ... OncLive will collaborate to raise awareness of the ... treatment, and other projects. Clinicians and other health ...
(Date:10/19/2014)... October 20, 2014 OCTOBER ... Meeting (ABIM). ABIM will take place ... information about ABIM 2014 is now available ... Delegates representing companies and organizations from all ... obtain information on the latest products and ...
(Date:10/19/2014)... The Asia-Pacific Speech Analytics market report ... with analysis and forecast of revenue. This market is ... $208 million by 2019, at a Compound Annual Growth ... Browse through the TOC of the Asia-Pacific Speech Analytics ... analysis provided. It also provides a glimpse of the ...
Breaking Biology Technology:Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4
... MedWaves, AveCure™ microwave coagulation-ablation (MWA) system uses ... (abnormal structures) safely, effectively, precisely and with repeatability. ... worldwide, including lesions in bone, kidney, liver, lung ... technology to treat lesions in other locations in ...
... LAUSANNE, Switzerland, and MALVERN, Pennsylvania, September 7, ... a global biopharmaceutical development specialist that focuses ... and Ascenta Therapeutics, Inc. (Ascenta), a privately-held, ... development of new medicines to treat cancer, ...
... portfolio of 16 Nanotechnology products and processes were ... organized to mark the fifty-second anniversary celebrations of ... portfolio, Director, Center of Excellence in Nanotechnology (CoEN) ... of products and processes demonstrates potential development of ...
Cached Biology Technology:MedWaves, Incorporated Announces Receipt of the Chinese State Food and Drug Administration (SFDA) Certification to Import and Sell Its Patented AveCure™ Microwave Ablation System and Devices 2MedWaves, Incorporated Announces Receipt of the Chinese State Food and Drug Administration (SFDA) Certification to Import and Sell Its Patented AveCure™ Microwave Ablation System and Devices 3Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T 2Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T 3AIT unveils portfolio of 16 nanotechnology products 2
(Date:10/14/2014)... the house fly genome for the first time, revealing ... insect that thrives in pathogen-rich dung piles and garbage ... journal Genome Biology , will increase understanding of ... quickly adapt to resist insecticides, which could lead to ... carry and transmit more than 100 human and animal ...
(Date:10/14/2014)... research team has discovered a new kind of stem cell ... that lines liver blood vessels, according to a study published ... existence of such a cell type contradicts current theory on ... may hold clues to origins of, and future treatment for, ... single cell into a complex being made up of more ...
(Date:10/14/2014)... 14, 2014 – Scientists from The Scripps Research Institute ... Institutes of Health (NIH) to lead an investigation of ... disease in Africa. The study aims to understand how ... die, while others survive the inflection. , "The ... mechanism of how Lassa fever virus causes disease and ...
Breaking Biology News(10 mins):House fly genome reveals expanded immune system 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
... Chestnut due to an Asian bark fungus accidentally introduced to ... the tree was highly valued for its strong, workable lumber ... bears relied upon the chestnut for food. Ongoing efforts ... in part because they rely on genetic cross breeding ...
... Each year, millions of monarch butterflies ( Danaus plexippus ... colonize eastern North America, but just how these delicate ... breeding range in spring has largely remained a mystery. ... led by Prof. Ryan Norris, Department of Integrative Biology, ...
... -- Findings from a first-of-its-kind study by Indiana University ... or fantasies -- can lead to female orgasm. ... phenomenon, sometimes called "coregasm" because of its association with ... media for years, said Debby Herbenick, co-director of the ...
Cached Biology News:UC research tests new tool to guide reintroduction of the American chestnut 2UC research tests new tool to guide reintroduction of the American chestnut 3Study reveals how monarch butterflies recolonize northern breeding range 2Study: Exercise can lead to female orgasm, sexual pleasure 2Study: Exercise can lead to female orgasm, sexual pleasure 3
Hucal Agx Antigen Expression Service Specificity: Hucal Agx ...
MHC. Sections include: the isolation and functional properties of antigen-presenting cells analysis of MHC class II endocytosis and peptide turnover analysis of signalling via MHC class II molecu...
... PAGE Cleavable ICAT Reagent ... Protein ID and Quantitation ... Electrophoresis (PAGE), isotope-coded affinity ... technology to facilitate the ...
Supplemental reagent for annexin V assay....
Biology Products: